CN111511722A - 一种制备噁拉戈利中间体的方法及其组合物 - Google Patents

一种制备噁拉戈利中间体的方法及其组合物 Download PDF

Info

Publication number
CN111511722A
CN111511722A CN201880081586.5A CN201880081586A CN111511722A CN 111511722 A CN111511722 A CN 111511722A CN 201880081586 A CN201880081586 A CN 201880081586A CN 111511722 A CN111511722 A CN 111511722A
Authority
CN
China
Prior art keywords
formula
compound
organic layer
group
stirring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880081586.5A
Other languages
English (en)
Other versions
CN111511722B (zh
Inventor
苏虎
郭效文
梁玉坤
石凯强
杨锦涛
何康
陶安平
黄鲁宁
安建国
陈茜
顾虹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Kesheng Pharmaceutical Research And Development Co ltd
Zhejiang Huahai Pharmaceutical Co Ltd
Original Assignee
Shanghai Kesheng Pharmaceutical Research And Development Co ltd
Zhejiang Huahai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Kesheng Pharmaceutical Research And Development Co ltd, Zhejiang Huahai Pharmaceutical Co Ltd filed Critical Shanghai Kesheng Pharmaceutical Research And Development Co ltd
Publication of CN111511722A publication Critical patent/CN111511722A/zh
Application granted granted Critical
Publication of CN111511722B publication Critical patent/CN111511722B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明涉及一种噁拉戈利钠中间体(式IV)的制备方法，所述方法通过下面的路线制备，该方法操作简捷安全，收率良好，同时环境污染小，有很好的经济效应，适宜工业生产，

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201880081586.5A 2017-12-27 2018-12-25 一种制备噁拉戈利中间体的方法及其组合物 Active CN111511722B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017114452525 2017-12-27
CN201711445252.5A CN109970663B (zh) 2017-12-27 2017-12-27 一种制备噁拉戈利中间体的方法
PCT/CN2018/123468 WO2019128983A1 (zh) 2017-12-27 2018-12-25 一种制备噁拉戈利中间体的方法及其组合物

Publications (2)

Publication Number Publication Date
CN111511722A true CN111511722A (zh) 2020-08-07
CN111511722B CN111511722B (zh) 2022-01-18

Family

ID=67063139

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201711445252.5A Active CN109970663B (zh) 2017-12-27 2017-12-27 一种制备噁拉戈利中间体的方法
CN201880081586.5A Active CN111511722B (zh) 2017-12-27 2018-12-25 一种制备噁拉戈利中间体的方法及其组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201711445252.5A Active CN109970663B (zh) 2017-12-27 2017-12-27 一种制备噁拉戈利中间体的方法

Country Status (4)

Country Link
US (1) US11365178B2 (zh)
EP (1) EP3733650A4 (zh)
CN (2) CN109970663B (zh)
WO (1) WO2019128983A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109970663B (zh) * 2017-12-27 2023-04-11 上海科胜药物研发有限公司 一种制备噁拉戈利中间体的方法
CN110501446B (zh) * 2019-08-28 2021-12-17 江苏海岸药业有限公司 一种噁拉戈利钠原料及其合成中间体的分析方法
CN110938038A (zh) * 2019-11-14 2020-03-31 上海星酶生物科技有限公司 一种c13h10f4n2o2的制备工艺
CN111333586A (zh) * 2020-02-19 2020-06-26 诚达药业股份有限公司 一种含有6-甲基尿嘧啶结构化合物的制备方法
CN111333548B (zh) * 2020-04-10 2022-04-26 江苏海悦康医药科技有限公司 1-(2-氟-6-(三氟甲基)苄基)脲的制备方法
CN111995584B (zh) * 2020-09-01 2022-03-29 常州工学院 恶拉格利中间体的制备方法
CN112159358B (zh) * 2020-10-26 2023-08-18 上海朴颐化学科技有限公司 一种噁拉戈利中间体的制备方法
CN115677598A (zh) * 2022-11-11 2023-02-03 南通常佑药业科技有限公司 一种合成嘧啶二酮类化合物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1819829A (zh) * 2003-07-07 2006-08-16 纽罗克里生物科学有限公司 作为促性激素释放激素受体拮抗剂的嘧啶－2,4－二酮衍生物
WO2009062087A1 (en) * 2007-11-07 2009-05-14 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
CN109970663A (zh) * 2017-12-27 2019-07-05 上海科胜药物研发有限公司 一种制备噁拉戈利中间体的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1819829A (zh) * 2003-07-07 2006-08-16 纽罗克里生物科学有限公司 作为促性激素释放激素受体拮抗剂的嘧啶－2,4－二酮衍生物
WO2009062087A1 (en) * 2007-11-07 2009-05-14 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
CN109970663A (zh) * 2017-12-27 2019-07-05 上海科胜药物研发有限公司 一种制备噁拉戈利中间体的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIREN ZHAO等: "5-Aryluracils as potent GnRH antagonists—Characterization of atropisomers", 《BIOORG. MED. CHEM. LETT》 *

Also Published As

Publication number Publication date
CN109970663A (zh) 2019-07-05
CN111511722B (zh) 2022-01-18
WO2019128983A1 (zh) 2019-07-04
CN109970663B (zh) 2023-04-11
EP3733650A4 (en) 2021-09-29
EP3733650A1 (en) 2020-11-04
US20200369625A1 (en) 2020-11-26
US11365178B2 (en) 2022-06-21

Similar Documents

Publication Publication Date Title
CN111511722B (zh) 一种制备噁拉戈利中间体的方法及其组合物
EP4293026A1 (en) High-purity thienopyrimidine compound and preparation method therefor
WO2018025722A1 (ja) ビオチンの中間体の製造方法、およびビオチンの製造方法
US20220204529A1 (en) Method for preparing lornoxicam
CN106256824A (zh) 一种高纯度德拉沙星葡甲胺盐的制备方法
CN110483549B (zh) 一种硝基咪唑吡喃类抗结核药物的制备方法
CN101337966B (zh) 一种制备高纯度伊立替康的方法
WO2004062571A2 (en) Substantially pure cilostazol and processes for making same
CN108752415A (zh) 一种非那雄胺手性杂质（5β-非那雄胺）合成及纯化方法
US20030166937A1 (en) Substantially pure cilostazol and processes for making same
AU2001284887A1 (en) Processes for preparing cilostazol
CN102464661A (zh) 一种5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸乙酯的制备方法
CN113185508A (zh) 一种制备高纯度高收率鲁拉西酮的方法
CN111848517A (zh) 一种依达拉奉的制备方法
CN109053585B (zh) 一种三氯苯达唑的合成方法
CN111100042B (zh) 一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法
CN110655549B (zh) 6β-甲泼尼龙的制备方法
JP6963435B2 (ja) ビオチンの中間体の製造方法、およびビオチンの製造方法
CN114437169B (zh) 一种屈螺酮关键中间体溴代物的合成方法
CN110156696B (zh) 一种1,4-二氯酞嗪的制备方法
CN112920114B (zh) 一种硫酸羟氯喹的合成方法
CN113045574B (zh) 二氮杂䓬衍生物的制备方法及其中间体
CN106966942B (zh) 一种依折麦布的制备方法
CN113173968A (zh) 一种依普利酮的纯化方法
WO2023100110A1 (en) Process for preparing brivaracetam

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant